Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 4Recruiting 3Terminated 2Unknown 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Endocrine 4NET 3Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Neuroendocrine Tumors 2Pulmonary Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × surufatinib × NET × Clear all
NCT07357623 2026-01-22

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

Shanghai Chest Hospital

Phase 2 Recruiting
96 enrolled
EndocrineNET

Pulmonary Neuroendocrine Tumor

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting
350 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡